Advanced kidney cancer: Treating the elderly

Fable Zustovich, Giacomo Novara

Research output: Contribution to journalArticlepeer-review


Advancing age represents the primary risk factor for renal tumors. Despite findings on the inhibition of angiogenesis that have led to six new drugs to treat metastatic renal cell carcinoma, elderly patients have not been fully represented in clinical trials. In addition, current opinions regarding nephrectomy in elderly patients are conflicting. Available data refer to the efficacy and safety of sorafenib, sunitinib, everolimus, bevacizumab and temsirolimus in patients aged 65 years and older; safety and efficacy data are available only for sunitinib, sorafenib, and everolimus in patients aged 70 years and older and only sorafenib has safety data for patients aged 75 years and older. A different approach based on evaluating comorbidities at baseline, risk of drug interactions and the impact of antitumor treatment in patients with polytherapy regimen is discussed. A decision-making algorithm is proposed to facilitate the selection of the best therapy for kidney tumors for a specific elderly patient profile.

Original languageEnglish
Pages (from-to)1389-1398
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number12
Publication statusPublished - 2013


  • Antiangiogenic
  • Bevacizumab
  • Carcinoma
  • Elderly
  • Everolimus
  • Renal
  • Sorafenib
  • Sunitinib
  • Temsirolimus
  • Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Advanced kidney cancer: Treating the elderly'. Together they form a unique fingerprint.

Cite this